May 6, 2026 04:18PM
Mar 25, 2026 05:24AM
Mar 24, 2026 08:54AM
Mar 24, 2026 06:39AM
Mar 23, 2026 04:16PM
Nov 6, 2025 04:21PM
Nov 5, 2025 04:15PM Context Therapeutics Reports Third Quarter 2025 Operating and Financial Results
Aug 6, 2025 04:11PM
May 7, 2025 04:17PM
May 7, 2025 04:09PM
Mar 24, 2025 05:43AM
Mar 20, 2025 04:22PM
Nov 7, 2024 06:27AM
Nov 6, 2024 04:06PM Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results
Aug 8, 2024 06:38AM
Aug 7, 2024 04:17PM
May 9, 2024 06:56AM
May 8, 2024 04:20PM
May 8, 2024 04:06PM
Mar 21, 2024 07:43AM
Nov 9, 2023 04:15PM Context Therapeutics Reports Third Quarter 2023 Operating and Financial Results
Aug 10, 2023 03:56PM
Aug 9, 2023 04:10PM
May 10, 2023 05:49PM
May 10, 2023 04:39PM
Mar 22, 2023 05:08PM
Mar 22, 2023 05:08PM
Jan 4, 2023 07:30AM Context Therapeutics® Highlights 2023 Corporate Priorities and Pipeline Milestones
Jan 4, 2023 07:30AM
Dec 8, 2022 07:30AM
Dec 8, 2022 07:30AM
Dec 8, 2022 07:30AM
Nov 9, 2022 04:14PM
Nov 9, 2022 04:14PM
Aug 11, 2022 04:01PM Context Therapeutics® Reports Second Quarter 2022 Operating and Financial Results
Aug 11, 2022 04:01PM
May 11, 2022 04:01PM
May 11, 2022 04:01PM
Mar 23, 2022 04:01PM
Mar 23, 2022 04:01PM
Dec 10, 2021 09:26AM
Dec 2, 2021 04:02PM Context Therapeutics (CNTX) Reports Q3 Net Loss of $1.4M, Cash and Cash Equivalents of $0.4M
Dec 2, 2021 04:01PM
Dec 2, 2021 04:01PM

1,199,633 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All